Executives from Canopy Growth CGC, -1.22% WEED, -1.27% and rival Aurora Cannabis Inc. ACB, -0.88% ACB, -0.83% both discussed their hemp operations on September-quarter earnings calls that included disappointing results related to early recreational pot sales. Aurora declined to comment on the latest developments and Canopy did not make executives available by the time of publication.
I have lower back pain with some arthritis and arthritis in my hands.ive recently tried CBD Oil. It really does work. I have the drops and ointment. They both work. Because of the back pain I never would have been able to go on a hike with my family. We had a lot of fun. And "No Pain", all day. I'm also Type 2 diabetic. Anxious to see what my A1C is next month. I'm a believer.
Although hemp can be successfully grown continuously for several years on the same land, rotation with other crops is desirable. A 3- or preferably 4-year rotation may involve cereals, clover or alfalfa for green manure, maize, and hemp. In Ontario it has been recommended that hemp not follow canola, edible beans, soybeans or sunflowers. However, according to Bócsa and Karus (1998), “it matters little what crops are grown prior to hemp.”
"Comparisons of industrial hemp to hydrocarbon or other conventional industrial feedstocks show that, generally, hemp requires substantially less energy for manufacturing, often is suited to less-toxic means of processing, and provides competitive product performance (especially in terms of durability, light weight, and strength), greater recyclability and/or biodegradability, and a number of value-added applications for byproducts and waste materials at either end of the product life cycle."
Specific city and county laws have been enacted to regulate how citizens and tourists may possess and consume marijuana. Penalties exist for driving while under the influence of marijuana. Someone driving under the influence of marijuana is considered impaired in both Colorado and Washington when five nanograms per milliliter (ng/mL) of blood or more of active THC is detected.
Concrete-like blocks made with hemp and lime have been used as an insulating material for construction. Such blocks are not strong enough to be used for structural elements; they must be supported by a brick, wood, or steel frame. However, hemp fibres are extremely strong and durable, and have been shown to be usable as a replacement for wood for many jobs, including creating very durable and breathable homes. The most common use of hemp lime in building is by casting the hemp and lime mix while wet around a timber frame with temporary shuttering, and tamping the mix to form a firm mass; after the removal of the temporary shuttering, the solidified hemp mix is then ready to be plastered with a lime plaster.
Hemp is completely different from marijuana in its function, cultivation and application. But these differences didn’t stop our political leaders from getting confused and accidentally grouping all Cannabis species as a Schedule I Drug and banning it in 1970 under the Controlled Substances Act. Even after 45 years, the government still seems to have some confusion in distinguishing the two plants. Although legislation is being made, progress has been slow.In its application, hemp and marijuana serve completely different purposes. Marijuana, as it is widely known, is used for medicinal or recreational purposes. Hemp is used in variety of other applications that marijuana couldn’t possibly be used in. These include healthy dietary supplements, skin products, clothing, and accessories. Overall, hemp is known to have over 25,000 possible applications.
Pain is physical suffering or discomfort typically caused by illness or injury. Chronic pain is defined as any pain lasting more than 12 weeks. It can persist for months or years. Opiates are the most common treatment for chronic pain, even though substantial research shows that they are not effective. About 60% of people suffering from chronic pain are women.
Particular difficulties face the clinician managing intractable patients afflicted with cancer-associated pain, neuropathic pain, and central pain states (eg, pain associated with multiple sclerosis) that are often inadequately treated with available opiates, antidepressants and anticonvulsant drugs. Physicians are seeking new approaches to treatment of these conditions but many remain concerned about increasing governmental scrutiny of their prescribing practices (Fishman 2006), prescription drug abuse or diversion. The entry of cannabinoid medicines to the pharmacopoeia offers a novel approach to the issue of chronic pain management, offering new hope to many, but also stoking the flames of controversy among politicians and the public alike.
Hi, I am new to trying CBD oil for chronic pain. I really do not know where to begin . For 14 yrs now I have been living with chronic back pain. I have had surgery, numerous shots, etc. I have been on pain ( opiods) for 14 yrs. I am looking to find something not only for my pain, depression, not sleeping ,anxiety, etc. I know that most my problems come from my chronic pain and being on pain meds for so long. Can anyone please recommend a CBD oil product and strength for me. I have been reading all the reviews and I just need someone to help. I have talked to my Doctor about it and he feels that I should try, but didn’t recommend what.
Cannador® (IKF-Berlin) is a cannabis extract administered in oral capsules, with differing figures as to THC:CBD ratios (reviewed in (Russo and Guy 2006)), generally approximately 2:1. Two pharmacokinetic studies on possibly related material have been reported (Nadulski et al 2005a; Nadulski et al 2005b). In a Phase III RCT employing Cannador in spasticity in multiple sclerosis (MS) (CAMS) (Zajicek et al 2003) (Table 1), no improvement was noted in the Ashworth Scale, but benefit was observed in spasm-associated pain on subjective measures. Both Marinol and Cannador produced reductions in pain scores in long-term follow-up (Zajicek et al 2005). Cannador was assayed in postherpetic neuralgia in 65 subjects with no observed benefit (Ernst et al 2005) (Table 1), and in 30 post-operative pain subjects (CANPOP) without opiates, with slight benefits, but prominent psychoactive sequelae (Holdcroft et al 2006) (Table 1).
Cannabis use is associated with increased recruitment of task-related areas, such as the dorsolateral prefrontal cortex, which is thought to reflect compensatory activity due to reduced processing efficiency. Cannabis use is also associated with downregulation of CB1 receptors. The magnitude of down regulation is associated with cumulative cannabis exposure, and is reversed after one month of abstinence. There is limited evidence that chronic cannabis use can reduce levels of glutamate metabolites in the human brain.
A limited number of studies have examined the effects of cannabis smoking on the respiratory system. Chronic heavy marijuana smoking is associated with coughing, production of sputum, wheezing, and other symptoms of chronic bronchitis. The available evidence does not support a causal relationship between cannabis use and chronic obstructive pulmonary disease. Short-term use of cannabis is associated with bronchodilation. Other side effects of cannabis use include cannabinoid hyperemesis syndrome.
Due to almost a century of misinformation about Cannabis, the distinction between Cannabis and its two primary species — hemp and marijuana — has become unclear to the many and some even consider the three plants to be one in the same. Because of this, the three terms are often used interchangeably, which has created difficulties when understanding the usage and benefits of Hemp vs Marijuana and Cannabis in general.
The health consequences of cannabis use in developing countries are largely unknown beacuse of limited and non-systematic research, but there is no reason a priori to expect that biological effects on individuals in these populations would be substantially different to what has been observed in developed countries. However, other consequences might be different given the cultural and social differences between countries.
Cohen has found that chronic conditions including autoimmune diseases and pain syndromes can be helped with a 6-mg under-the-tongue tincture (the fastest delivery system) or a 25-mg capsule taken twice a day. Dosages for topical products like lotions are especially hard to determine—there’s no clarity on how much CBD gets into the system through the skin.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This change applies only to FDA-approved products containing no more than 0.1 percent THC. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.
“This is a really powerful compound,” says Mikhail Kogan, the medical director of the George Washington University Center for Integrative Medicine. “I’ve seen it work for a lot of my patients.” He prescribes high-CBD strains of cannabis regularly for such illnesses as epilepsy, post-traumatic stress disorder, anxiety, autoimmune disorders, autism and insomnia.
Smaller companies focused on CBD beverages, such as New Age Beverages Corp. NBEV, -1.47% , have been targeted by investors, but some firms have used CBD-related announcements to pump stock prices as well as fuel excitement in a compound that scientists do not fully understand. Other companies operating in the sector will benefit too: Charlotte’s Web Holdings Inc. CWBHF, +5.11% has focused on a range of CBD products, capturing about 17% market share in 2017 with sales in 3,000 retail locations, according to PI Financial research.
A number of people who have used cannabis to fight cancer, have later died of the cancer. I’m concerned that what may have killed many of these people, is that a minor change in the growing conditions of the cannabis plants, reduced the potency of whichever ingredients have the anti-cancer effect. The people kept dosing themselves with their oils or tinctures, but the oils and tinctures no longer contained enough cancer-fighting agents to defeat the cancer, and the people had no way of measuring this.
Sativex® (GW Pharmaceuticals) is an oromucosal whole cannabis-based spray combining a CB1 partial agonist (THC) with a cannabinoid system modulator (CBD), minor cannabinoids and terpenoids plus ethanol and propylene glycol excipients and peppermint flavoring (McPartland and Russo 2001; Russo and Guy 2006). It was approved by Health Canada in June 2005 for prescription for central neuropathic pain in multiple sclerosis, and in August 2007, it was additionally approved for treatment of cancer pain unresponsive to optimized opioid therapy. Sativex is a highly standardized pharmaceutical product derived from two Cannabis sativa chemovars following Good Agricultural Practice (GAP) (de Meijer 2004), yielding Tetranabinex® (predominantly-THC extract) and Nabidiolex® (predominantly-CBD extract) in a 1:1 ratio. Each 100 μL pump-action oromucosal Sativex spray actuation provides 2.7 mg of THC and 2.5 mg of CBD. Pharmacokinetic data are available, and indicate plasma half lives of 85 minutes for THC, 130 minutes for 11-hydroxy-THC and 100 minutes for CBD (Guy and Robson 2003). Sativex effects commence in 15–40 minutes, an interval that permits symptomatic dose titration. A very favorable adverse event profile has been observed in over 2500 patient years of exposure in over 2000 experimental subjects. Patients most often ascertain an individual stable dosage within 7–10 days that provides therapeutic relief without unwanted psychotropic effects (often in the range of 8–10 sprays per day). In all RCTs, Sativex was adjunctively added to optimal drug regimens in subjects with intractable symptoms, those often termed “untreatable.” Sativex is also available by named patient prescription in the UK and the Catalonia region of Spain. An Investigational New Drug (IND) application to study Sativex in advanced clinical trials in the USA was approved by the FDA in January 2006 in patients with intractable cancer pain.
The findings imply that cannabidiol can also be a healthy alternative for patients who have got accustomed to powerful painkiller doses. CBD does not have any steroid properties, and it is an anti-inflammatory drug that is less powerful than analgesics based on opioids. But, CBD is much more prescribed because of its non-side-effect causing properties.
Various strains of "medical marijuana" are found to have a significant variation in the ratios of CBD-to-THC, and are known to contain other non-psychotropic cannabinoids. Any psychoactive marijuana, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. Non-psychoactive hemp (also commonly-termed industrial hemp), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis. Certain standards are required for legal growing, cultivating, and producing the hemp plant. The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0.3%.
Hemp was a prominent crop in the United States until 1937, when the Marihuana Tax Act virtually obliterated the American hemp industry. During World War II, hemp saw a resurgence in the U.S., as it was used extensively to make military items ranging from uniforms to canvas and rope. The United States Department of Agriculture even released a short documentary, “Hemp for Victory,” in 1942, which promoted hemp as a useful crop for the war cause.
With that stereotype now changing in addition to the outbreak of legal marketplaces in 33 states, we’re seeing a boom in cross-industry trends where major corporate and investment players are starting to enter the cannabis sector or at least signal willingness to do so. These trends are proving so strong that companies are starting to think it’s important to get in the game or risk being left behind later. That’s why major brands are either dipping a toe into the water or laying the groundwork for a cannonball-level splash when the Green Rush finally breaks.
As marijuana is legalized in more and more states, the wellness world has whipped itself into a frenzy over a non-intoxicating cannabis derivative called cannabidiol. CBD products can be found on the internet and in health-food stores, wellness catalogs and even bookstores. (A bookstore in downtown Boulder, Colorado, displays a case of CBD products between the cash register and the stacks of new releases.) Celebrities like Gwyneth Paltrow, disgraced cyclist1 Floyd Landis and former Denver Broncos quarterback Jake Plummer are all touting CBD products, and according to Bon Appétit, CBD-infused lattes have become “the wellness world’s new favorite drink.”
Despite some relatively tough talk from regulatory bodies, it can seem like they’re trying to close the barn door after the horse got out. CBD is already everywhere, and people are curious about it for reasons that seem to go far beyond trendiness, such as financial precariousness and health-care costs. “People are panicking and looking for things. They’re like, ‘What if I don’t have insurance because I get laid off? What can I replace my meds with?’” says Donahue, the Allure editor. CBD fits neatly with a growing distrust in technology and in the pharmaceutical industry, and America’s moderating view of cannabis means that many people see CBD as a safer alternative for anxiety or pain that’s worth trying.
CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is for its effectiveness in treating some of the cruelest childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which typically don’t respond to antiseizure medications. In numerous studies, CBD was able to reduce the number of seizures, and in some cases it was able to stop them altogether. Videos of the effects of CBD on these children and their seizures are readily available on the Internet for viewing, and they are quite striking. Recently the FDA approved the first ever cannabis-derived medicine for these conditions, Epidiolex, which contains CBD.
“Hemp” refers primarily to Cannabis sativa L. (Cannabaceae), although the term has been applied to dozens of species representing at least 22 genera, often prominent fiber crops. For examples, Manila hemp (abaca) is Musa textilis Née, sisal hemp is Agave sisalina Perrine, and sunn hemp is Crotolaria juncea L. Especially confusing is the phrase “Indian hemp,” which has been used both for narcotic Asian land races of C. sativa (so-called C. indica Lamarck of India) and Apocynum cannabinum L., which was used by North American Indians as a fiber plant. Cannabis sativa is a multi-purpose plant that has been domesticated for bast (phloem) fiber in the stem, a multi-purpose fixed oil in the “seeds” (achenes), and an intoxicating resin secreted by epidermal glands. The common names hemp and marijuana (much less frequently spelled marihuana) have been applied loosely to all three forms, although historically hemp has been used primarily for the fiber cultigen and its fiber preparations, and marijuana for the drug cultigen and its drug preparations. The current hemp industry is making great efforts to point out that “hemp is not marijuana.” Italicized, Cannabis refers to the biological name of the plant (only one species of this genus is commonly recognized, C. sativa L.). Non-italicized, “cannabis” is a generic abstraction, widely used as a noun and adjective, and commonly (often loosely) used both for cannabis plants and/or any or all of the intoxicant preparations made from them.
CBD does not appear to have any psychotropic ("high") effects such as those caused by ∆9-THC in marijuana, but may have anti-anxiety and anti-psychotic effects. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical marijuana" (with varying degrees of psychotropic effects and deficits in executive function) – from "medical CBD therapies” which would commonly present as having a reduced or non-psychoactive side-effect profile.